candesartan has been researched along with Migraine Disorders in 17 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe the use of the antihypertensive, candesartan, with hydrochlorothiazide (ECARD Combination Tablets LD) as a preventive therapy that decreased the frequency of migraine accompanied by premonitory leg edema." | 3.79 | Migraine treated using a prophylactic combination of candesartan and hydrochlorothiazide (ECARD Combination Tablets LD). ( Akiyama, H; Hasegawa, Y, 2013) |
| " Rates of adverse events were similar for patients using and not using preventive medications." | 2.90 | Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. ( Ailani, J; Baygani, S; Hundemer, HP; Krege, JH; Loo, LS; Port, M; Schim, J, 2019) |
| "Candesartan was non-inferior to propranolol (and vice versa)." | 2.79 | A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. ( Aamodt, AH; Gravdahl, GB; Hagen, K; Linde, M; Sand, T; Stovner, LJ; Tronvik, E, 2014) |
| "The treatment of migraine depends on the frequency, severity and concomitant diseases." | 2.52 | [Role of antihypertensive drugs in the treatment of migraine]. ( Fehér, G; Pusch, G, 2015) |
| "Mild migraine attack can be treated with acetaminophen or NSAIDs either alone or combined with metoclopramide." | 2.52 | [Update on Current Care Guideline: Migraine]. ( , 2015) |
| "Lamotrigine is ineffective for migraine prevention (Level A)." | 2.48 | Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. ( Argoff, C; Ashman, E; Dodick, DW; Freitag, F; Holland, S; Silberstein, SD, 2012) |
| "ACE inhibitors and ARBs have migraine prophylaxis activity similar to that of some currently utilized agents." | 2.46 | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. ( Bailey, EK; Gales, BJ; Gales, MA; Reed, AN, 2010) |
| "Eighty-four patients (70%) had chronic migraine and 53 (42." | 1.62 | Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. ( García-Azorín, D; Guerrero, ÁL; Martínez-Pías, E; Planchuelo-Gómez, Á; Sánchez-Rodríguez, C; Sierra, Á, 2021) |
| "Eighty-one patients (chronic migraine, n = 68) were included in the final analysis." | 1.56 | Candesartan in migraine prevention: results from a retrospective real-world study. ( Filippi, M; Goadsby, PJ; Lastarria Perez, CP; Messina, R, 2020) |
| "A pregnant young woman with a severe migraine is prescribed candesartan, an angiotensin II type 1 receptor antagonist (AT II antagonists)." | 1.36 | Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome. ( Haaland, K, 2010) |
| "347 migraine patients aged 18-68 (155 migraine without aura (MoA), 187 migraine with aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years of age were included in the study." | 1.35 | Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. ( Bovim, G; Gladwin, AJ; Owen, K; Schrader, H; Stovner, LJ; Tronvik, E; White, LR, 2008) |
| "Thus candesartan is considered to be a unique, attractive choice of prophylactic agent for migraine complicated by hypertension." | 1.32 | Efficacy of candesartan in the treatment of migraine in hypertensive patients. ( Owada, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Messina, R | 1 |
| Lastarria Perez, CP | 1 |
| Filippi, M | 1 |
| Goadsby, PJ | 1 |
| Sánchez-Rodríguez, C | 1 |
| Sierra, Á | 1 |
| Planchuelo-Gómez, Á | 1 |
| Martínez-Pías, E | 1 |
| Guerrero, ÁL | 1 |
| García-Azorín, D | 1 |
| Morris, B | 1 |
| Neher, J | 1 |
| Safranek, S | 1 |
| Loo, LS | 1 |
| Ailani, J | 1 |
| Schim, J | 1 |
| Baygani, S | 1 |
| Hundemer, HP | 1 |
| Port, M | 1 |
| Krege, JH | 1 |
| Stovner, LJ | 4 |
| Linde, M | 1 |
| Gravdahl, GB | 1 |
| Tronvik, E | 3 |
| Aamodt, AH | 1 |
| Sand, T | 2 |
| Hagen, K | 1 |
| Fehér, G | 1 |
| Pusch, G | 1 |
| Haaland, K | 1 |
| Gales, BJ | 1 |
| Bailey, EK | 1 |
| Reed, AN | 1 |
| Gales, MA | 1 |
| Silberstein, SD | 1 |
| Holland, S | 1 |
| Freitag, F | 1 |
| Dodick, DW | 1 |
| Argoff, C | 1 |
| Ashman, E | 1 |
| Akiyama, H | 1 |
| Hasegawa, Y | 1 |
| Helde, G | 1 |
| Bovim, G | 2 |
| Owada, K | 1 |
| Rapoport, AM | 1 |
| Bigal, ME | 1 |
| White, LR | 1 |
| Gladwin, AJ | 1 |
| Owen, K | 1 |
| Schrader, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study[NCT02439320] | Phase 3 | 2,231 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)[NCT02605174] | Phase 3 | 3,005 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| CandeSpartan Study Candesartan Spanish Response-prediction and Tolerability Study Observational Study on Response Predictors and Tolerability of Candesartan in Usual Clinical Practice[NCT04138316] | 85 participants (Actual) | Observational [Patient Registry] | 2020-01-02 | Completed | |||
| Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study[NCT00884663] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study[NCT00184587] | Phase 2 | 40 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section (NCT02439320)
Timeframe: Baseline up to 11 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| 100 mg Lasmiditan | 0 |
| 200 mg Lasmiditan | 2 |
| Placebo | 1 |
The percentage of participants without nausea. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 64.6 |
| 200 mg Lasmiditan | 64.1 |
| Placebo | 62.1 |
The percentage of participants without phonophobia. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 60.7 |
| 200 mg Lasmiditan | 58.7 |
| Placebo | 52.5 |
The percentage of participants without photophobia. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 53.9 |
| 200 mg Lasmiditan | 51.5 |
| Placebo | 38.1 |
The percentage of participants defined as mild, moderate, or severe headache pain becoming none. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 28.2 |
| 200 mg Lasmiditan | 32.2 |
| Placebo | 15.3 |
The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 40.9 |
| 200 mg Lasmiditan | 40.7 |
| Placebo | 29.5 |
The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 59.4 |
| 200 mg Lasmiditan | 59.5 |
| Placebo | 42.2 |
Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 26.2 |
| 200 mg Lasmiditan | 20.7 |
| Placebo | 46.0 |
Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). (NCT02439320)
Timeframe: Anytime 24-48 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 0 |
| 200 mg Lasmiditan | 0 |
| Placebo | 0 |
Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). (NCT02439320)
Timeframe: Anytime between 2-24 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 8.9 |
| 200 mg Lasmiditan | 7.9 |
| Placebo | 11.7 |
Participants who received study drug and which became pain free at 2 hours post-dose and worsened again up to 48 hours post-dose. (NCT02439320)
Timeframe: From 2 hours post dose up to 48 hours
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 8.4 |
| 200 mg Lasmiditan | 10.1 |
| Placebo | 5.1 |
Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study (NCT02439320)
Timeframe: 6 months prior to enrolling in study to end of study (Up to 11 Weeks) within 7 days of treating a single migraine attack
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 Months prior to enrolling | During time of study | |
| 100 mg Lasmiditan/100 mg Lasmiditan | 4.4 | 0.9 |
| 100 mg Lasmiditan/Placebo | 4.6 | 0.5 |
| 200 mg Lasmiditan/200 mg Lasmiditan | 3.0 | 0.2 |
| 200 mg Lasmiditan/Placebo | 2.5 | 0.5 |
| Placebo/Placebo | 2.8 | 0.6 |
The number of participants with headache recurrence (moderate or severe at baseline which became pain-free at 2 hours post dose and worsened again up to 48 hours post dose) (NCT02605174)
Timeframe: From 2 Hours Post Dose Up to 48 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Lasmiditan 50 mg | 38 |
| Lasmiditan 100 mg | 44 |
| Lasmiditan 200 mg | 52 |
| Placebo | 26 |
Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section (NCT02605174)
Timeframe: From Baseline Up to End of Study (Up to 11 Weeks)
| Intervention | participants (Number) |
|---|---|
| Lasmiditan 50 mg | 167 |
| Lasmiditan 100 mg | 230 |
| Lasmiditan 200 mg | 253 |
| Placebo | 75 |
The percentage of participants defined as mild, moderate, or severe headache pain becoming none. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 28.6 |
| Lasmiditan 100 mg | 31.4 |
| Lasmiditan 200 mg | 38.8 |
| Placebo | 21.3 |
The percentage of participant without nausea. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 68.7 |
| Lasmiditan 100 mg | 71.8 |
| Lasmiditan 200 mg | 70.4 |
| Placebo | 70.3 |
The percentage of participants who used rescue medication. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 31.9 |
| Lasmiditan 100 mg | 26.4 |
| Lasmiditan 200 mg | 18.9 |
| Placebo | 40.8 |
The percentage of participants who used rescue medication. (NCT02605174)
Timeframe: From 2 Hours Post Dose Up to 24 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 8.9 |
| Lasmiditan 100 mg | 6.3 |
| Lasmiditan 200 mg | 7.4 |
| Placebo | 8.7 |
The percentage of participants who used rescue medication. (NCT02605174)
Timeframe: From 24 Post Dose Up to 48 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 0.0 |
| Lasmiditan 100 mg | 0.0 |
| Lasmiditan 200 mg | 0.0 |
| Placebo | 0.0 |
The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 40.8 |
| Lasmiditan 100 mg | 44.2 |
| Lasmiditan 200 mg | 48.7 |
| Placebo | 33.5 |
The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 59.0 |
| Lasmiditan 100 mg | 64.8 |
| Lasmiditan 200 mg | 65.0 |
| Placebo | 47.7 |
The percentage of participants without phonophobia. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 61.2 |
| Lasmiditan 100 mg | 64.8 |
| Lasmiditan 200 mg | 65.3 |
| Placebo | 53.5 |
The percentage of participants without photophobia. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 51.2 |
| Lasmiditan 100 mg | 56.4 |
| Lasmiditan 200 mg | 58.2 |
| Placebo | 43.2 |
Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study (NCT02605174)
Timeframe: 6 Months Prior to Enrolling in Study to End of Study (Up to 11 Weeks) Within 7 Days of Treating a Single Migraine Attack
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months prior to enrolling | During time of study | |
| Lasmiditan 100 mg/Lasmiditan 100 mg | 2.8 | 0.5 |
| Lasmiditan 100 mg/Placebo | 2.4 | 0 |
| Lasmiditan 200 mg/Lasmiditan 200 mg | 3.2 | 0.9 |
| Lasmiditan 200 mg/Placebo | 3.3 | 0.5 |
| Lasmiditan 50 mg/Lasmiditan 50 mg | 4.7 | 0.5 |
| Lasmiditan 50 mg/Placebo | 2.2 | 0 |
| Placebo/Placebo | 2.9 | 0.6 |
6 reviews available for candesartan and Migraine Disorders
| Article | Year |
|---|---|
Clinical Inquiries. How effectively do ACE inhibitors and ARBs prevent migraines?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2018 |
[Role of antihypertensive drugs in the treatment of migraine].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2015 |
[Update on Current Care Guideline: Migraine].
Topics: Acetaminophen; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opi | 2015 |
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2010 |
Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2012 |
Preventive migraine therapy: what is new.
Topics: Analgesics; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Second-Generation; Anti | 2004 |
3 trials available for candesartan and Migraine Disorders
| Article | Year |
|---|---|
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
8 other studies available for candesartan and Migraine Disorders
| Article | Year |
|---|---|
Candesartan in migraine prevention: results from a retrospective real-world study.
Topics: Benzimidazoles; Biphenyl Compounds; Humans; London; Migraine Disorders; Retrospective Studies; Tetra | 2020 |
Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study.
Topics: Benzimidazoles; Biphenyl Compounds; Disease Management; Duration of Therapy; Female; Headache; Human | 2021 |
Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2010 |
Migraine treated using a prophylactic combination of candesartan and hydrochlorothiazide (ECARD Combination Tablets LD).
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Combinations; Edema; Female | 2013 |
BP drug for migraine prevention.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 2003 |
Efficacy of candesartan in the treatment of migraine in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Humans; | 2004 |
Migraine prophylaxis with drugs influencing the renin-angiotensin system.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2008 |